Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients

Abstract

Background: Mutations affecting ERBB3 are rare but diffuse across cancer types. Besides the case report of an effective treatment by HER2 double blockade in an ERBB3 mutated breast cancer patient, the clinical efficacy of treatments targeting ERBB3 mutations remain largely unknown 1. The objective of our study was to evaluate the efficacy of approved HER3 partners' inhibitors in the ERBB3 mutant population. Methods: We retrospectively evaluated the clinical efficacy of HER3 partner's inhibitor in ERBB3 mutant tumors. ERBB3 mutations were detected using Targeted Gene Panel Sequencing in patients enrolled in our molecular screening program (MOSCATO 01).